Taysha Gene Therapies, Inc.
NASDAQ:TSHABiotechnology
+$0.10 today
- Market cap
- $1.30B
- Beta
- 1.18
- P/E (TTM)
- -17.7
- EPS (TTM)
- -$0.35
Volume 3.38M
Average 2.73M
TSHA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Taysha Gene Therapies, Inc.NASDAQ: TSHA
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of $38.64M rose 91.8% year over year, ahead of the +85.8% change in trailing-twelve-month research & development. Sequentially, it rose 14.3% from the prior quarter. Over 3 fiscal years it compounded at -1.8% a year.
Context
- Research & development amounted to 884.1% of revenue in FY2025, up 92.1 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +91.8% holds above the trailing-twelve-month pace of +85.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 86.4M USD
- Year-over-year change
- +30.9%
- 4-year CAGR
- -10.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 86.4M | +30.9% |
| FY2024 | 2024-12-31 | 66M | +16.2% |
| FY2023 | 2023-12-31 | 56.78M | -37.7% |
| FY2022 | 2022-12-31 | 91.17M | -30.9% |
| FY2021 | 2021-12-31 | 131.94M | — |
Research & Development vs competitors
How TSHA compares with its peers on the latest reported figures
- TSHA's LTM Jun 2026 research & development of $122.56M is the 6th highest of the 9 companies compared; the peer median is $132.64M.
- Its year-over-year change of +85.8% is the highest of 9, against a peer median of -1.0%.
- Research & development amounts to 2234.4% of revenue for TSHA, versus a peer median of 249.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $902.58M | -34.5% | +20.2% | 41.3% | |
| LTM Mar 2026 | $228.65M | +12.8% | -2.0% | 260.4% | |
| LTM Mar 2026 | $219.98M | +42.7% | +34.6% | 249.3% | |
| LTM Mar 2026 | $137.53M | -14.3% | -5.0% | — | |
| LTM Mar 2026 | $127.75M | -3.1% | +30.4% | 350.1% | |
| LTM Jun 2026 | $122.56M | +85.8% | -1.8% | 2234.4% | |
| LTM Mar 2026 | $82.4M | +26.5% | +16.4% | — | |
| LTM Mar 2026 | $26.43M | -28.8% | -2.5% | 181.7% | |
| LTM Mar 2026 | $19.2M | +1.2% | +17.6% | — | |
| Peer median (excluding TSHA) | $132.64M | -1.0% | +17.0% | 249.3% | |
Competitors are the stored peer set for TSHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 2.5M | 15.45M | 8.33M | 9.77M |
| Cost of Revenue | 0 | 2.49M | 0 | 0 | 0 |
| Gross Profit | 0 | 15K | 15.45M | 8.33M | 9.77M |
| Gross Margin | — | 0.6% | 100.0% | 100.0% | 100.0% |
| Research & Development | 131.94M | 91.17M | 56.78M | 66M | 86.4M |
| Selling, General & Admin | 41.32M | 34.87M | 30.05M | 28.95M | 33.87M |
| Operating Expenses | 173.27M | 126.04M | 87.89M | 99.79M | 120.27M |
| Depreciation & Amortization | 492K | 2.49M | 1.37M | 1.25M | 1.15M |
| EBITDA | (172.6M) | (159.73M) | (105.2M) | (87.95M) | (107.79M) |
| EBITDA Margin | — | -6384.1% | -680.8% | -1055.5% | -1102.9% |
| Operating Income | (173.27M) | (126.03M) | (72.44M) | (91.46M) | (110.5M) |
| Operating Margin | — | -5037.1% | -468.8% | -1097.6% | -1130.6% |
| Interest Income | 172K | 249K | 3.57M | 6.94M | 9.22M |
| Interest Expense | 1.43M | 3.8M | 5M | 102K | 63K |
| Other Income / Expenses | (1.26M) | (39.99M) | (39.13M) | 2.16M | 1.5M |
| Income Before Tax | (174.52M) | (166.01M) | (111.57M) | (89.3M) | (109M) |
| Pre-Tax Margin | — | -6635.3% | -722.1% | -1071.6% | -1115.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (174.52M) | (166.01M) | (111.57M) | (89.3M) | (109M) |
| Net Margin | — | -6635.3% | -722.1% | -1071.6% | -1115.3% |
| EPS (Basic) | (4.64) | (3.78) | (0.96) | (0.36) | (0.34) |
| EPS (Diluted) | (4.64) | (3.78) | (0.96) | (0.36) | (0.34) |
| Weighted Avg Shares | 37.65M | 43.95M | 116.12M | 250.13M | 319.71M |
| Weighted Avg Shares (Diluted) | 37.65M | 43.95M | 116.12M | 250.13M | 319.71M |
Taysha Gene Therapies, Inc.
NASDAQ:TSHA
Intrinsic Alpha fair value
Locked
Current Price
$3.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.